Chapter 04 Limits of Human Perception Figure 1: The human eye has evolved to detect visible light in a very thin spectrum, and is functionally limited by density of photoreceptors and compression of visual data sent along the optic nerve.
Full Text of Announcement Section I. All Common Fund initiatives invite investigators to develop bold, innovative, and often risky approaches to address problems that may seem intractable or to seize new opportunities that offer the potential for transformation of research processes.
The simplicity and broad applicability of targeted and programmable genome editing approaches, including but not limited to those based on CRISPR-Cas9, raise the possibility of a fundamentally new way to treat a variety of rare genetic diseases, as well as numerous therapeutic strategies for common diseases.
However, many challenges need to be overcome before such techniques could be widely used in the clinic. Participants in a NIH workshop identified several research areas in need of investment, including optimized genome editors, specifically targeted delivery systems, and more predictive animal models and studies.
Although research in each of these fields has been very active, efforts have focused on the needs of individual studies and not on overall procedures for improving and testing the safety and efficacy of genome editing approaches.
To maximize the potential of genome editing technology to treat as many Human rm as possible, the SGCE program has been developed to accelerate the translation of genome editing technology into clinical applications. The key components of the SCGE program include: The SCGE DCC will make the results, tools and technologies developed under this program widely available to facilitate adoption for translation into clinical applications.
The deliverables of the SCGE program will be a collection of tools, methods, data, and best practices that will accelerate development and testing of new treatments for many diseases i.
The SCGE program will involve collaborative research by a partnership of genome editing experts, delivery systems experts, animal model creators and testers, and assay developers to produce validated techniques and knowledge through exchange of expertise, information and research tools.
Awardees from all five SCGE program components will form a consortium, governed by a steering committee of investigators and NIH staff that will develop consensus policies and procedures for consortium-wide activities such as data and resource sharing.
It is expected that all awardees will collaborate to accelerate the translation of genome editing technologies into treatments for human disease. Research Objectives The objective of this Funding Opportunity Announcement is to support research aiming to develop innovative genome editing systems with improved specificity, efficiency, or functionality over currently available systems.
Expanding the repertoire of genome editing tools would accelerate the development of novel genome editing therapeutics to treat a broad array of rare and common diseases. Research Scope This program will support the development of novel and optimized alternative genome editing platforms to existing in vivo genome editing complexes.
CRISPR-Cas is the newest and most widely adopted tool in the genome editing repertoire, which already consists of diverse methodologies including mega nucleases, transposons, recombinases, protein nucleic acids, transcriptional activator-like effector nuclease TALENs and Zinc-finger nucleases ZFNs.
Creative engineering of CRISPR-associated nucleases including fusion with other editing enzymes, transcription factors or chromatin modifiers has already led to programmable editing of genomic DNA or RNA without double-stranded DNA cleavage as well as directed modulation of endogenous gene expression.
Nevertheless, there continues to be a need to invest in fundamental advances in genome editing technology with novel biological capabilities, and improved efficiency and precision, to maximize their clinical applicability for the treatment of a variety of diseases.
Expanding the repertoire of genome editors will greatly increase the power of genome editing for therapeutic development. Improvements in programmable nucleases are being rapidly generated, but significant drawbacks remain to be addressed.
For example, off-target cleavage, which may result in undesired genomic rearrangements and other genotoxic effects, has been reported.This is a file from the Wikimedia regardbouddhiste.comation from its description page there is shown below.
Commons is a freely licensed media file repository. You can help. Quest to Identify Functional Elements in the Human Genome. Completing the human genome reference sequence was a milestone in modern biology.
The considerable challenge that remained was to identify and delineate the structures of all genes and other functional elements.
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Expanding the Human Genome Engineering Repertoire (U01 Clinical Trial Not Allowed) RFA-RM RMOD.
Welcome to the Office of Compliance, Equal Opportunity and Affirmative Action (EOAA) at Kent State University.
Mission Statement. The mission of the Office of Compliance, EOAA is to ensure equal access to employment and educational opportunities in support of the university's commitment to equal opportunity, affirmative action, and diversity.
Resource Management is the home of Central Stores, Central Receiving, Surplus Property, Postal Services, F&S Human Resources, F&S IT, the Office of Contracts and Real Estate Management, and the F&S Business Office.
Human Resources for the University of Oklahoma. Serving Faculty and Staff in Norman, Oklahoma City, and Tulsa campuses.